A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

Boston Scientific

Status and phase: Active, not recruiting; Phase 2

Conditions: Nonalcoholic Steatohepatitis (NASH)

Treatments: Drug: BOS-580; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT04880031

BOS-580-201

Details and patient eligibility

About

This is a safety study to evaluate BOS-580 administered subcutaneously with repeated dosing over 12 weeks in Part A or 24 weeks in Part B. Part C is multicenter, open-label safety study in which all participants who completed part B and are interested and met the criteria for part C will be treated with one dose of BOS-580 for 24 weeks.

Enrollment: 205 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria (Part A and Part B):

• Participant is either male or female and 18 to 75 years of age inclusive, at the time of signing the informed consent
• Obese participants with body mass index (BMI) of ≥ 27 kg/m^2
• Hepatic fat fraction (HFF) measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) ≥8%
• Liver fibrosis assessment based on a vibration controlled transient elastography (VCTE) liver stiffness measurement (LSM) score of 7.0 to 9.9 kPa (Part A only) inclusive or 7.0 to 20.0 kPa (Part B only) inclusive and Liver injury assessment measured by aspartate aminotransferase (AST) >25U/L. A qualifying historical biopsy (confirmed eligibility based on the central pathology read) supersedes the LSM, controlled attenuation parameter (CAP) score criteria and AST criteria.
• Histopathologically confirmed F2 or F3 stage NASH on a diagnostic liver biopsy performed during Screening or within 6 months prior to the first day of dosing for historical biopsies (Part B only).
• History or presence of at least 2 of 4 components of metabolic syndrome: obesity/overweight, dyslipidemia (high triglycerides and/or low high density lipoprotein [HDL]), type 2 diabetes with elevated glycated hemoglobin (HbA1c), and hypertension.

Inclusion Criteria (Part C):

• Participant must have completed the Part B of the study.
• Participant willing to undergo liver biopsy at Week 56
• NASH F stage <F4 at 24 week assessment in Part B

Exclusion Criteria (Part A and Part B):

• Documented clinical, laboratory or radiologic evidence of cirrhosis (compensated or decompensated)
• Triglycerides ≥ 500 mg/dL
• Change in body weight (more than 5% self-reported OR 5 kg self-reported change during the previous 3 months from Screening, whichever is smaller)
• History of type 1 diabetes, diabetic ketoacidosis, or positive glutamic acid decarboxylase (GAD) auto-antibodies (latent autoimmune diabetes in adults)
• Hemoglobin A1c > 9.5%
• Subjects with a condition that requires substantial anticoagulant medication may not be eligible for the study enrollment (e.g., deep vein thrombosis).

Exclusion Criteria (Part C):

• Subjects that received their 24 week dose in Part B > 10 weeks prior to enrollment into Part C

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

205 participants in 7 patient groups

Cohort A1: BOS-580 Dose 1 or placebo (PBO)

Experimental group

Treatment:

Drug: Placebo

Drug: BOS-580

Cohort A2: BOS-580 Dose 2 or PBO

Experimental group

Treatment:

Drug: Placebo

Drug: BOS-580

Cohort A3: BOS-580 Dose 3 or PBO

Experimental group

Treatment:

Drug: Placebo

Drug: BOS-580

Cohort A4: BOS-580 Dose 4 or PBO

Experimental group

Treatment:

Drug: Placebo

Drug: BOS-580

Cohort A5: BOS-580 Dose 5 or PBO

Experimental group

Treatment:

Drug: Placebo

Drug: BOS-580

Cohort B: BOS-580 Dose 1 or PBO

Experimental group

Treatment:

Drug: Placebo

Drug: BOS-580

Cohort C: BOS-580 Dose 1

Experimental group

Treatment:

Drug: BOS-580